1374239-71-0

1374239-71-0 structure

1374239-71-0 structure

Name: BTK-IN-18
Chemical Name: BTK-IN-18
CAS Number: 1374239-71-0
Molecular Formula: C₂₀H₂₂Cl₂N₆O
Molecular Weight: 433.33
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK Btk
Create Date: 2023-04-04 09:44:06
Modify Date: 2024-04-03 08:33:26
BTK-IN-18 is a potent, reversible BTK inhibitor with an IC50 of 0.002 µM. BTK-IN-18 inhibits both CD69 and CD86 in vivo[1].

Name	BTK-IN-18

Description	BTK-IN-18 is a potent, reversible BTK inhibitor with an IC50 of 0.002 µM. BTK-IN-18 inhibits both CD69 and CD86 in vivo[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Btk
In Vivo	BTK-IN-18 (化合物 41; 10, 25, 45 mg/kg; 腹腔给药; 单剂量) 对 CD69 和 CD86 产生强烈的剂量依赖性抑制[1]。 BTK-IN-18 (静脉给药; 1 mg/kg) 在大鼠中的 T1/2 为 5.3 小时，CL 为 19 mL/min/kg，Vss 为 1.3 L/kg[1]。 Animal Model: Mice[1] Dosage: 10, 25, 45 mg/kg Administration: IP; single dose Result: Caused robust dose-dependent inhibition of both CD69 and CD86 (74.8 %, 50.3 %, and 21.5 % respectively). Animal Model: Dosage: Administration: Result: Pharmacokinetic Parameters of BTK-IN-18 in rats[1]. IV (1 mg/kg) PO (5 mg/kg) Tmax (h) 1.6 Cmax (h∗mg/mL) 321 AUCinfi (h∗mg/mL) 1013 1421 t1/2 (ng/mL) 5.3 CL (mL/min/kg) 19 Vss (L/kg) 1.3 F (%) 23%
References	[1]. George H Vandeveer, et al. Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model. Bioorg Med Chem Lett. 2022 Dec 17;80:129108.

Molecular Formula	C₂₀H₂₂Cl₂N₆O
Molecular Weight	433.33